Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
05 06 2019
Historique:
entrez: 22 6 2019
pubmed: 22 6 2019
medline: 29 2 2020
Statut: epublish

Résumé

To mitigate the opioid overdose crisis, states have implemented a variety of legal interventions aimed at increasing access to the opioid antagonist naloxone. Recently, Virginia and Vermont mandated the coprescription of naloxone for potentially at-risk patients. To assess the association between naloxone coprescription legal mandates and naloxone dispensing in retail pharmacies. This was a population-based, state-level cohort study. The sample included all prescriptions dispensed for naloxone in the retail pharmacy setting contained in IQVIA's national prescription audit, which represents 90% of all retail pharmacies in the United States. The unit of observation was state-month and the study period was January 1, 2011, to December 31, 2017. State legal intervention mandating naloxone coprescription. Number of naloxone prescriptions dispensed. State rates of naloxone prescriptions dispensed per month per 100 000 standard population were calculated. The rate of naloxone dispensing increased after implementation of legal mandates for naloxone coprescription. An estimated 88 naloxone prescriptions per 100 000 were dispensed in Virginia and 111 prescriptions per 100 000 were dispensed in Vermont during the first full month the legal requirement was effective. In comparison, 16 naloxone prescriptions per 100 000 were dispensed in the 10 states (including the District of Columbia) with the highest opioid overdose death rates and 6 prescriptions per 100 000 were dispensed in the 39 remaining states. The number of naloxone prescriptions dispensed was associated with the legal mandate for naloxone coprescription (incidence rate ratio [IRR], 7.75; 95% CI, 1.22-49.35). Implementation of the naloxone coprescription mandate was associated with an estimated 214 additional naloxone prescriptions dispensed per month in the period following the mandates, holding all other variables constant. Among covariates, naloxone access laws (IRR, 1.37; 1.05-1.78), opioid overdose death rates (IRR, 1.06; 95% CI, 1.04-1.08), the percentage of naloxone prescriptions paid by third-party payers (IRR 1.009; 1.008-1.010), and time (IRR, 1.06; 95% CI, 1.05-1.07) were significantly associated with naloxone prescription dispensing. These study findings suggest that legally mandated naloxone prescription for those at risk for opioid overdose may be associated with substantial increases in naloxone dispensing and further reduction in opioid-related harm.

Identifiants

pubmed: 31225895
pii: 2736179
doi: 10.1001/jamanetworkopen.2019.6215
pmc: PMC6593960
doi:

Substances chimiques

Analgesics, Opioid 0
Narcotic Antagonists 0
Naloxone 36B82AMQ7N

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e196215

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR000117
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001998
Pays : United States

Références

JAMA. 2018 May 22;319(20):2073-2074
pubmed: 29621389
Ann Intern Med. 2014 Apr 1;160(7):441-50
pubmed: 24687067
JAMA. 2016 Apr 19;315(15):1624-45
pubmed: 26977696
JAMA Netw Open. 2019 Feb 1;2(2):e187621
pubmed: 30707224
J Am Pharm Assoc (2003). 2017 Mar - Apr;57(2S):S180-S184
pubmed: 28073688
Addict Behav. 2018 Nov;86:90-95
pubmed: 29610001
J Gen Intern Med. 2010 Apr;25(4):284-90
pubmed: 20131023
Epidemiology. 2010 Jul;21(4):467-74
pubmed: 20220526
J Manag Care Pharm. 2008 Jul-Aug;14(6):553-60
pubmed: 18693779
Drug Alcohol Depend. 2018 Mar 1;184:26-32
pubmed: 29402676
JAMA Intern Med. 2016 May 1;176(5):583-4
pubmed: 27043188
J Addict Med. 2014 May-Jun;8(3):153-63
pubmed: 24874759
N Engl J Med. 2016 Dec 8;375(23):2213-2215
pubmed: 27959694
Pharmacoepidemiol Drug Saf. 2016 Jul;25(7):852-3
pubmed: 27222197
Drug Alcohol Depend. 2018 Aug 1;189:37-41
pubmed: 29860058
N Engl J Med. 2014 May 29;370(22):2063-6
pubmed: 24758595
Epidemiol Infect. 2012 Jun;140(6):1087-94
pubmed: 21875452
Drug Alcohol Depend. 2018 Oct 1;191:361-364
pubmed: 30195192
MMWR Morb Mortal Wkly Rep. 2019 Jan 11;68(1):1-5
pubmed: 30629574

Auteurs

Minji Sohn (M)

College of Pharmacy, Ferris State University, Big Rapids, Michigan.

Jeffery C Talbert (JC)

Institute for Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky, Lexington.

Zhengyan Huang (Z)

Department of Biostatistics, College of Public Health, University of Kentucky, Lexington.

Michelle R Lofwall (MR)

Center on Drug and Alcohol Research, University of Kentucky, Lexington.

Patricia R Freeman (PR)

Institute for Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky, Lexington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH